FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of polynucleotide encoding a chimeric antigen receptor (hereinafter – CAR); it can be used for the treatment of cancer characterized by expression of CD20. Polynucleotide is proposed, containing a polynucleotide sequence encoding CAR with SEQ ID NO:26, capable of specifically binding CD20. An immune host cell containing the specified polynucleotide and capable of expressing encoded CAR is used as a part of compositions and combinations for the treatment of cancer expressing CD20.
EFFECT: invention provides activation of T-cells presenting CAR to CD20 in the presence of antibodies to CD20.
74 cl, 25 dwg, 2 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| MUC16-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USE | 2019 |
|
RU2795198C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| CELL | 2014 |
|
RU2732236C2 |
